Loading…
← CockpitCompetitor Analysis › 6535.TWO Lumosa Therapeutics Co LtdOpen in the cockpit ↗

Lumosa Therapeutics Co Ltd6535.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Major
Momentum neutral 58
Mkt cap
$406M
US dollars, full cap
Free float
64%
of shares outstanding
$/day
$766,889
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-39.4 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
103 days
1 Mar 2027
Close · TWDNT$83.30
1D-4.7%
1W+3.1%
1M+9.8%
3M-3.2%
6M-36.9%
YTD-57.2%
1Y-60.6%
ATR %6.0%
52w lowhigh62.5% off high

What Lumosa Therapeutics does

Employees: 39

Lumosa Therapeutics at a glance

Size Lumosa Therapeutics (6535.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $406M, the 508th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$83.30 on 18 Nov 2026.

Performance Over six months the shares fell 36.9%, against -17.2% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th lowest of 20 in its peer set.

Growth Revenue fell 24.8% over the last twelve months (peer median +3.4%); the operating margin is -803.3% (peer median 4.6%).

Valuation It trades at 399.1× enterprise value to sales against a peer median of 3.7× (most expensive of 18).

Capital Return on invested capital runs 39.4 points below its cost of capital (5.0% WACC).

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 836535.TWO 66
Six months, rebased to 100: Lumosa Therapeutics against the median of its 20 peers (local-currency closes).

Lumosa Therapeutics financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$32.0MNT$35.8MNT$39.2MNT$56.9MNT$26.6M
Revenue growth—-8%-31%+114%—
Gross profitNT$15.7MNT$21.8MNT$17.6MNT$24.8M-NT$2.08M
EBITDA-NT$247M-NT$322M-NT$349M-NT$352M-NT$284M
Net income-NT$395M-NT$341M-NT$425M-NT$238M-NT$495M
Free cash flow-NT$237M-NT$357M-NT$293M-NT$335M-NT$303M
Capital expenditureNT$0NT$668,000NT$450,000NT$15.0MNT$2.29M
Total debtNT$1.74MNT$6.92MNT$8.48MNT$12.6MNT$4.69M

Quarterly statements and history in the cockpit →

Lumosa Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%000931002864002581CTMXRZLT7871300636219A603139TVGN0010604114048410AVTX42C3005346535.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. Lumosa Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+2,000%+4,000%+6,000%0×200×400×0009310028647871219A04841042C6535.TWORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lumosa Therapeutics is the large dot.

Lumosa Therapeutics competitors and peer comparison

How Lumosa Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lumosa Therapeutics against its 20 peers (data as of 18 Nov 2026)
Measure6535.TWOPeer medianRank in peer set
1-month return+9.8%-11.1%3rd highest of 21
6-month return-36.9%-17.2%5th lowest of 20
Distance from 52-week high-62.5%-42.0%5th lowest of 21
Revenue growth (TTM)-24.8%+3.4%3rd lowest of 19
Operating margin-803.3%4.6%2nd lowest of 19
EV / Sales399.1×3.7×most expensive of 18
ROIC minus cost of capital-39.4 pp-1.4 pp3rd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Lumosa Therapeutics 6535.TWOTaiwan$406M-37%-25%-803%399.1×n/an/a
Beijing Centergate Technologies (Holding) 000931.SZChina$406M-18%-16%2%1.9×9.2%+6.7%
Shaanxi Panlong Pharmaceutical 002864.SZChina$407M-15%-16%7%1.7×-3.2%+11.2%
Shandong Sinobioway Biomedicine 002581.SZChina$405M-24%+91%-65%7.9×n/an/a
CytomX Therapeutics CTMXUnited States$410M-49%-88%-676%4.7×n/an/a
Rezolute RZLTUnited States$411M+32%n/an/an/an/an/a
Elixiron Immunotherapeutics (Cayman) 7871.TWOTaiwan$412M+64%+6,162%-194%119.7×n/an/a
Jiangxi Synergy Pharmaceutical 300636.SZChina$398M-13%-3%2%3.4×14.9%+13.7%
Teyi Pharmaceutical 002728.SZChina$419M-12%-7%7%3.2×24.4%+8.0%
Heartseed 219A.TJapan$392M+53%+197%9%21.9×46.5%+73.2%
Shaanxi Kanghui Pharmaceutical Co 603139.SSChina$421M-31%+1%-39%7.1×n/an/a
Tevogen TVGNUnited States$422M-38%n/an/an/an/an/a
JW Pharmaceutical 001060.KSSouth Korea$423M-26%+9%13%0.7×-15.4%+7.2%
Beijing Foyou Pharma 601089.SSChina$423M-27%+5%10%0.2×n/an/a
Synmosa Biopharma 4114.TWOTaiwan$423M-1%+21%10%2.2×5.4%+15.3%
Hyundai Bioscience 048410.KSSouth Korea$424M-50%+78%-580%164.0×n/an/a
Anhui Sunhere Pharmaceutical Excipients 300452.SZChina$388M-17%+9%19%2.2×-5.5%+12.2%
Avalo Therapeutics AVTXUnited States$387M-59%-69%-161,961%n/an/an/a
iX Biopharma 42C.SISingapore$387M+28%-12%-140%71.6×n/an/a
Shukra Pharmaceuticals SHUKRAPHAR.NSIndia$387Mn/a+222%54%32.0×n/an/a
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZChina$386M-2%-21%8%3.7×20.9%+28.2%

Questions

Which companies are Lumosa Therapeutics's closest peers?
The cockpit's peer set: Beijing Centergate Technologies (Holding) (000931.SZ), Shaanxi Panlong Pharmaceutical (002864.SZ), Shandong Sinobioway Biomedicine (002581.SZ), CytomX Therapeutics (CTMX), Rezolute (RZLT), Elixiron Immunotherapeutics (Cayman) (7871.TWO), Jiangxi Synergy Pharmaceutical (300636.SZ), Teyi Pharmaceutical (002728.SZ).
Is Lumosa Therapeutics expensive compared with its peers?
On ev / sales it trades at 399.1× against a peer median of 3.7×, most expensive of 18 in its peer set.
How has Lumosa Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -36.9% against -17.2% for the median peer; over one year -60.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.